A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors - Trial NCT04842630
Access comprehensive clinical trial information for NCT04842630 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu HengRui Medicine Co., Ltd. and is currently Recruiting. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jiangsu HengRui Medicine Co., Ltd.
Timeline & Enrollment
Phase 1
Apr 08, 2021
Oct 15, 2023
Primary Outcome
Dose Limited Toxicity (DLT),Maximum tolerable dose (MTD),Recommended dose for phase II (RP2D)
Summary
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SHR-1916
 in adult patients with locally advanced or metastatic solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04842630
Non-Device Trial